FDA puts par­tial hold on Gilead’s CD47 hope­ful in AML

The FDA put a par­tial clin­i­cal hold on Gilead’s ma­grolimab for acute myeloid leukemia, a month af­ter the com­pa­ny scrapped late-stage de­vel­op­ment of the CD47 can­di­date in myelodys­plas­tic syn­dromes.

Gilead said Mon­day morn­ing it stopped screen­ing and en­rolling new pa­tients in US tri­als study­ing the drug in AML, though pa­tients al­ready en­rolled in the stud­ies can con­tin­ue treat­ment.

The par­tial hold af­fects two Phase III stud­ies: EN­HANCE-2, test­ing the drug with azac­i­ti­dine in pa­tients with un­treat­ed AML and TP53 mu­ta­tions, and EN­HANCE-3, which com­bines ma­grolimab with vene­to­clax and azac­i­ti­dine for pa­tients with AML who are in­el­i­gi­ble for chemother­a­py, a Gilead spokesper­son told End­points News. Gilead’s ex­pand­ed ac­cess pro­gram is al­so on pause.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER